Development and external validation of a novel nomogram model for predicting postoperative recurrence-free survival in non-muscle-invasive bladder cancer
BackgroundTransurethral resection of the bladder tumor with or without adjuvant intravesical instillation (IVI) has been the standard treatment for non-muscle-invasive bladder cancer (NMIBC), whereas a high percentage of patients still experience local tumor recurrence and disease progression after...
Main Authors: | Li Ding, Xiaobin Deng, Wentao Xia, Kun Wang, Yang Zhang, Yan Zhang, Xianfeng Shao, Junqi Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-11-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1070043/full |
Similar Items
-
Preoperative Systemic Inflammatory Markers as a Significant Prognostic Factor After TURBT in Patients with Non-Muscle-Invasive Bladder Cancer
by: Ding L, et al.
Published: (2023-01-01) -
Replacement Instead of Discontinuation of Bacillus Calmette-Guérin Instillation in Non-Muscle-Invasive Bladder Cancer
by: Po-Ting Lin, et al.
Published: (2023-02-01) -
Preoperative systemic immune‐inflammation index as a significant prognostic factor after TURBT in patients with non‐muscle‐invasive bladder cancer: A retrospective study based on propensity score matching analysis
by: Li Ding, et al.
Published: (2023-03-01) -
Instillation Strategies for Non-Muscle-Invasive Bladder Cancer in the Bacillus Calmette-Guerin Shortage Era: A Simple Solution for BCG Discontinuation
by: Lin PT, et al.
Published: (2022-11-01) -
TULA DUAL: Trans Urethral Laser Ablation of recurrent bladder tumors in outpatient setting
by: Rosario Leonardi, et al.
Published: (2023-02-01)